The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe
Richard Nicholas(Swansea University), Rod Middleton(Swansea University), Melinda Magyari(University of Copenhagen), Tim Spelman(Peter Doherty Institute), Dana Horáková(Charles University), Helmut Butzkueven(Monash Alfred Psychiatry Research centre), Pernilla Klyve(Karolinska Institutet), Carol Lines(Novartis (Switzerland)), Anneke van der Walt(The Alfred Hospital), Alexander Stahmann(Unknown), David Ellenberger(L3S Research Center), James Witts(Swansea University), Jan Hillert, Tim Friede(FIND), Ryan Ramanujam(Karolinska Institutet), Annalaura Lerede(Imperial College London), Luigi Pontieri(Rigshospitalet), Vladimir Bezlyak(Novartis (Switzerland)), Jiří Drahota(Charles University), Ali Manouchehrinia(Karolinska Institutet), Lars Forsberg, Hanna Joensen(Rigshospitalet), Anna Glaser(Karolinska Institutet), Jeff Rodgers(Swansea University)
Cited by 6
Related Papers
Multiple Sclerosis Severity Score
|Neurology|2005|957
Multiple sclerosis progression: time for a new mechanism-driven framework
|The Lancet Neurology|2022|624
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12
|Journal of Clinical Oncology|2019|536
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy
|Kidney International|2011|361